Business Description
Andros Pharmaceuticals Co Ltd
ISIN : TW0006917008
Description
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.19 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.35 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 7.26 | |||||
| Beneish M-Score | -3.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -43.3 | |||||
| 3-Year EBITDA Growth Rate | -17.8 | |||||
| 3-Year EPS without NRI Growth Rate | -12 | |||||
| 3-Year FCF Growth Rate | -6.6 | |||||
| 3-Year Book Growth Rate | 46.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.46 | |||||
| 9-Day RSI | 67.8 | |||||
| 14-Day RSI | 62.38 | |||||
| 6-1 Month Momentum % | -17.94 | |||||
| 12-1 Month Momentum % | -34.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 21.94 | |||||
| Quick Ratio | 21.88 | |||||
| Cash Ratio | 21.37 | |||||
| Days Inventory | 1704.42 | |||||
| Days Sales Outstanding | 48.14 | |||||
| Days Payable | 8.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.5 | |||||
| Shareholder Yield % | 0.62 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.28 | |||||
| Operating Margin % | -20406.72 | |||||
| Net Margin % | -18248.68 | |||||
| FCF Margin % | -17511.75 | |||||
| ROE % | -19.61 | |||||
| ROA % | -17.41 | |||||
| ROIC % | -105.48 | |||||
| ROC (Joel Greenblatt) % | -263.69 | |||||
| ROCE % | -18.28 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1825 | |||||
| PB Ratio | 1.87 | |||||
| Price-to-Tangible-Book | 1.87 | |||||
| EV-to-EBIT | -5.86 | |||||
| EV-to-EBITDA | -6.37 | |||||
| EV-to-Revenue | 1064.16 | |||||
| EV-to-FCF | -5.1 | |||||
| Price-to-Net-Current-Asset-Value | 2.23 | |||||
| Price-to-Net-Cash | 2.3 | |||||
| Earnings Yield (Greenblatt) % | -17.05 | |||||
| FCF Yield % | -8.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Andros Pharmaceuticals Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 0.417 | ||
| EPS (TTM) (NT$) | -1.89 | ||
| Beta | 0 | ||
| Volatility % | 23.49 | ||
| 14-Day RSI | 62.38 | ||
| 14-Day ATR (NT$) | 0.726586 | ||
| 20-Day SMA (NT$) | 16.69 | ||
| 12-1 Month Momentum % | -34.67 | ||
| 52-Week Range (NT$) | 15.4 - 25.8 | ||
| Shares Outstanding (Mil) | 44.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Andros Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Andros Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Andros Pharmaceuticals Co Ltd Frequently Asked Questions
What is Andros Pharmaceuticals Co Ltd(ROCO:6917)'s stock price today?
The current price of ROCO:6917 is NT$18.25. The 52 week high of ROCO:6917 is NT$25.80 and 52 week low is NT$15.40.
When is next earnings date of Andros Pharmaceuticals Co Ltd(ROCO:6917)?
The next earnings date of Andros Pharmaceuticals Co Ltd(ROCO:6917) is .
Does Andros Pharmaceuticals Co Ltd(ROCO:6917) pay dividends? If so, how much?
Andros Pharmaceuticals Co Ltd(ROCO:6917) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers